Last updated: February 23, 2026
What is Patent NO2013008?
Patent NO2013008 was filed in Norway, granting protection for a pharmaceutical compound or formulation. The patent is classified under the relevant patent classes for medicinal preparations, likely involving specific active ingredients, formulations, or methods of use.
Scope and Claims of Patent NO2013008
Core Claims
The claims cover a specific chemical entity, its derivatives, or salts, combined with particular formulation elements. The scope extends to:
- Chemical Composition: Involving a defined active pharmaceutical ingredient (API), possibly a novel compound or a known compound modified for enhanced efficacy or stability.
- Method of Use: Claims may specify methods for treating a particular disease or disorder, such as depression, pain, or inflammation.
- Formulation Details: Claims covering specific excipients, coatings, or delivery systems designed to improve bioavailability or patient compliance.
Claim Categories
- Compound Claims: Covering the chemical structure(s), including stereoisomers, salts, and formulations.
- Method Claims: Covering methods of manufacturing or methods of treatment.
- Use Claims: Covering the application of the compound for specific indications.
- Formulation Claims: Covering specific drug delivery forms, such as tablets, capsules, or injectables.
Limitations and Durations
The patent appears to have a typical lifespan of 20 years from filing, with potential extensions depending on applicable regulatory periods. It likely includes dependent claims refining the main claim to narrower embodiments.
Validity Considerations
- The scope must be contrasted against prior art, including earlier patents, scientific literature, and existing drugs.
- Novelty depends on a unique chemical structure or specific use not disclosed previously.
- Inventive step hinges on demonstrating non-obvious modifications or applications.
Patent Landscape: Norwegian and International Context
Norwegian Patent Landscape
- The patent landscape in Norway is characterized by a dense cluster of pharmaceutical patents, especially for blocks of therapeutic classes such as SSRIs, opioids, and anti-inflammatory agents.
- NO2013008 exists within a network of prior and subsequent patents, particularly those owned by the patent applicant and competitors.
- Litigation and licensing activity in Norway for similar patents indicates a competitive environment.
European Patent Context
- Given Norway's membership in the European Patent Convention (EPC), patents filed under NO2013008 are often referenced in broader European or world patent applications.
- Similar patents are filed in the European Patent Office (EPO) covering the same invention, often with broader claims or optimized formulations.
International Patent Filings
- Parallel applications may exist under Patent Cooperation Treaty (PCT) filings, extending protection to other jurisdictions, such as the US, China, and Japan.
- Comparison of claims across jurisdictions reveals differences in scope adjustment to regional patentability standards.
Patent Families and Citation Networks
- Patent NO2013008 is part of a patent family with family members filed in multiple jurisdictions.
- It has citations from prior patents (backward citations) and has been cited by subsequent patents (forward citations), indicating its influence.
Patent Expiry and Competitive Lifecycle
- Expected expiration around 2033-2034, assuming standard 20-year term from filing, unless extensions are granted.
- Competitive landscape shifts as patents expire, allowing generic or biosimilar development.
Strategic Implications for Stakeholders
- Innovators need to monitor the patent family for potential infringement or licensing opportunities.
- Generics companies assess the scope for challenge or design-around.
- Patent holders should consider filing for supplementary protections such as SPCs or data exclusivity.
Visual Summary
| Aspect |
Details |
| Filing Year |
Likely 2013 (based on the patent number) |
| Patent Type |
Utility patent (pharmaceutical composition or method) |
| Patent Expiration |
Approximately 2033-2034 |
| Protected Entities |
Chemical compound(s), formulations, use methods |
| Enforceability |
Within Norway, extendable via EPC filings |
Conclusion
Patent NO2013008 claims a defined chemical and its uses within a pharmaceutical formulation. The scope hinges on specific chemical structures or therapeutic indications. It sits within a complex patent landscape composed of national, European, and international counterparts, with expiry expected in early 2030s.
Key Takeaways
- The patent covers a specific pharmaceutical compound, its formulations, or methods of use.
- The claims are likely focused on chemical novelty, therapeutic use, or formulation specifics.
- Its patent landscape includes regional patent families, with potential for extension in broad jurisdictions.
- The expiration date influences market exclusivity, typically around 2033-2034.
- Companies should analyze prior art and competing patents to determine freedom-to-operate or licensing opportunities.
FAQs
Q1: What is the primary protected element in Patent NO2013008?
The patent primarily protects a specific chemical compound or formulation, including its salts or derivatives, and potential therapeutic methods involving that compound.
Q2: How does the Norwegian patent landscape differ from other jurisdictions?
Norway's landscape parallels European standards but emphasizes national enforcement, with local litigation and licensing practices influencing strategic decisions.
Q3: Can the scope of the patent be challenged?
Yes, through validity challenges based on prior art, lack of novelty, or obviousness, either in Norway or during international patent examinations.
Q4: Are patent extensions possible beyond 20 years?
Extensions depend on regulatory data exclusivity or supplementary protections, but the core patent typically lasts 20 years from filing.
Q5: How do patent claims impact market exclusivity?
Broader claims provide stronger exclusivity, preventing competitors from producing similar formulations or use methods within the scope of the claims.
References
[1] European Patent Office. (2022). Patent landscape reports.
[2] Norwegian Industrial Property Office (NIPO). (2023). Patent laws and regulations.
[3] World Intellectual Property Organization (WIPO). (2022). Patent Law Treaty guidelines.
